社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
evauoz
IP属地:未知
+关注
帖子 · 107
帖子 · 107
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
evauoz
evauoz
·
2021-12-28
Sell?
U.S. regulators step up probe into Hyundai, Kia engine fires
Dec 27 (Reuters) -The U.S. auto safety agency has stepped up its probe into engine fires that have p
U.S. regulators step up probe into Hyundai, Kia engine fires
看
2,167
回复
1
点赞
4
编组 21备份 2
分享
举报
evauoz
evauoz
·
2021-12-27
Buy?
3 Dividend Stocks to Buy If the Market Crashes in 2022
The next crash is always around the corner, so get ready.
3 Dividend Stocks to Buy If the Market Crashes in 2022
看
2,156
回复
2
点赞
1
编组 21备份 2
分享
举报
evauoz
evauoz
·
2021-12-26
Buy?
3 Stocking Stuffer Stocks You Can Buy for Less Than $10 Apiece
If you're looking for last-minute holiday deals for your portfolio, here are three growing companies trading in the single digits.
3 Stocking Stuffer Stocks You Can Buy for Less Than $10 Apiece
看
1,665
回复
1
点赞
1
编组 21备份 2
分享
举报
evauoz
evauoz
·
2021-12-25
Buy?
Can This Top Blue Chip Stock Handle Soaring Inflation?
We are in strange times right now, so how companies navigate the current environment is vital to their success.
Can This Top Blue Chip Stock Handle Soaring Inflation?
看
1,853
回复
2
点赞
7
编组 21备份 2
分享
举报
evauoz
evauoz
·
2021-12-24
Buy?
Is Amazon Stock A Buy Right Now As Epic Battle With Walmart Escalates
Amazon(AMZN) plans to build its first large-format retail stores, making a new foray into physical o
Is Amazon Stock A Buy Right Now As Epic Battle With Walmart Escalates
看
1,503
回复
2
点赞
2
编组 21备份 2
分享
举报
evauoz
evauoz
·
2021-12-23
Buy?
Cathie Wood Loads Up Another $800K In This Chinese Tesla Rival Ahead Of Its Overseas Expansion
Cathie Wood’s Ark Investment Management on Friday loaded up another 18,000 shares — worth about $823
Cathie Wood Loads Up Another $800K In This Chinese Tesla Rival Ahead Of Its Overseas Expansion
看
1,547
回复
2
点赞
1
编组 21备份 2
分享
举报
evauoz
evauoz
·
2021-12-22
Buy?
Travel and leisure stocks gained in early trading
Travel and leisure stocks gained in early trading. UAl, AAL, DAL and LUV shares were up between 4% a
Travel and leisure stocks gained in early trading
看
1,476
回复
1
点赞
5
编组 21备份 2
分享
举报
evauoz
evauoz
·
2021-12-21
Buy?
3 Growth Stocks That Could Skyrocket 50% or More in 2022, According to Wall Street
There are good reasons for Wall Street analysts to be bullish about these stocks.
3 Growth Stocks That Could Skyrocket 50% or More in 2022, According to Wall Street
看
2,552
回复
4
点赞
3
编组 21备份 2
分享
举报
evauoz
evauoz
·
2021-12-20
Sell?
Omicron Fears Ignite Market Selloff Just as Traders Clear Books
(Bloomberg) -- Just as investors were wrapping up this year’s trading, the threat of new lockdowns s
Omicron Fears Ignite Market Selloff Just as Traders Clear Books
看
2,559
回复
2
点赞
3
编组 21备份 2
分享
举报
evauoz
evauoz
·
2021-12-19
Buy?
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade
The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade
看
2,384
回复
1
点赞
5
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4087513826666000","uuid":"4087513826666000","gmtCreate":1624410763393,"gmtModify":1624441405718,"name":"evauoz","pinyin":"evauoz","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":16,"headSize":324,"tweetSize":107,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":3,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":696658588,"gmtCreate":1640689058253,"gmtModify":1640689058449,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Sell?","listText":"Sell?","text":"Sell?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696658588","repostId":"2194610717","repostType":4,"repost":{"id":"2194610717","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640689014,"share":"https://ttm.financial/m/news/2194610717?lang=&edition=full","pubTime":"2021-12-28 18:56","market":"us","language":"en","title":"U.S. regulators step up probe into Hyundai, Kia engine fires","url":"https://stock-news.laohu8.com/highlight/detail?id=2194610717","media":"Reuters","summary":"Dec 27 (Reuters) -The U.S. auto safety agency has stepped up its probe into engine fires that have p","content":"<p>Dec 27 (Reuters) -The U.S. auto safety agency has stepped up its probe into engine fires that have plagued some Hyundai Motor Co and Kia Motors Corp vehicles for over six years.</p>\n<p>The National Highway Traffic Safety Administration (NHTSA) said it had opened an \"engineering analysis\" covering about 3 million vehicles to evaluate, among other things, the efficacy of recalls initiated by the two automakers. The agency added that it was aware of 161 fires occurring potentially due to engine failures.</p>\n<p>An engineering analysis is the next step in a process that could lead to a recall, although sometimes NHTSA closes such probes without requiring any action.</p>\n<p>The agency had opened an investigation in 2019 covering the 2011-2014 Kia Optima and Sorento and the 2010-2015 Kia Soul, along with the 2011-2014 Hyundai Sonata and Santa Fe to investigate instances of non-crash fires.</p>\n<p>Hyundai said on Monday it continues to fully cooperate with NHTSA in regards to non-collision engine fires. Kia did not respond to a request for comment.</p>\n<p>The two South Korean companies had agreed to a record $210 million civil penalty last year after regulators said they failed to recall 1.6 million vehicles for engine issues in a timely fashion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. regulators step up probe into Hyundai, Kia engine fires</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. regulators step up probe into Hyundai, Kia engine fires\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-28 18:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 27 (Reuters) -The U.S. auto safety agency has stepped up its probe into engine fires that have plagued some Hyundai Motor Co and Kia Motors Corp vehicles for over six years.</p>\n<p>The National Highway Traffic Safety Administration (NHTSA) said it had opened an \"engineering analysis\" covering about 3 million vehicles to evaluate, among other things, the efficacy of recalls initiated by the two automakers. The agency added that it was aware of 161 fires occurring potentially due to engine failures.</p>\n<p>An engineering analysis is the next step in a process that could lead to a recall, although sometimes NHTSA closes such probes without requiring any action.</p>\n<p>The agency had opened an investigation in 2019 covering the 2011-2014 Kia Optima and Sorento and the 2010-2015 Kia Soul, along with the 2011-2014 Hyundai Sonata and Santa Fe to investigate instances of non-crash fires.</p>\n<p>Hyundai said on Monday it continues to fully cooperate with NHTSA in regards to non-collision engine fires. Kia did not respond to a request for comment.</p>\n<p>The two South Korean companies had agreed to a record $210 million civil penalty last year after regulators said they failed to recall 1.6 million vehicles for engine issues in a timely fashion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KIMTF":"Kia Motors Corp.","HYEVF":"Hyundai Elevator Co Ltd."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194610717","content_text":"Dec 27 (Reuters) -The U.S. auto safety agency has stepped up its probe into engine fires that have plagued some Hyundai Motor Co and Kia Motors Corp vehicles for over six years.\nThe National Highway Traffic Safety Administration (NHTSA) said it had opened an \"engineering analysis\" covering about 3 million vehicles to evaluate, among other things, the efficacy of recalls initiated by the two automakers. The agency added that it was aware of 161 fires occurring potentially due to engine failures.\nAn engineering analysis is the next step in a process that could lead to a recall, although sometimes NHTSA closes such probes without requiring any action.\nThe agency had opened an investigation in 2019 covering the 2011-2014 Kia Optima and Sorento and the 2010-2015 Kia Soul, along with the 2011-2014 Hyundai Sonata and Santa Fe to investigate instances of non-crash fires.\nHyundai said on Monday it continues to fully cooperate with NHTSA in regards to non-collision engine fires. Kia did not respond to a request for comment.\nThe two South Korean companies had agreed to a record $210 million civil penalty last year after regulators said they failed to recall 1.6 million vehicles for engine issues in a timely fashion.","news_type":1,"symbols_score_info":{"HYEVF":0.9,"HYUD.UK":0.9,"KIMTF":0.9}},"isVote":1,"tweetType":1,"viewCount":2167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696061999,"gmtCreate":1640576778166,"gmtModify":1640576778367,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696061999","repostId":"2194717735","repostType":4,"repost":{"id":"2194717735","kind":"highlight","pubTimestamp":1640574360,"share":"https://ttm.financial/m/news/2194717735?lang=&edition=full","pubTime":"2021-12-27 11:06","market":"us","language":"en","title":"3 Dividend Stocks to Buy If the Market Crashes in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2194717735","media":"Motley Fool","summary":"The next crash is always around the corner, so get ready.","content":"<p>Market crashes happen, and they tend to drag down the best stocks along with the rest of the market. It's impossible to predict the timing and severity of the next downturn, but it's easy to imagine <a href=\"https://laohu8.com/S/AONE.U\">one</a> occurring in the near term.</p>\n<p>The omicron variant keeps threatening to pinch the global economy. If the latest variant of concern quickly fizzles out, rising inflation could prompt the Federal Reserve to raise interest rates.</p>\n<p>These three companies make reliable dividend payments in good times and bad. Their stocks are up near 52-week highs at the moment, but an overall market downturn could push them down to highly attractive prices. Here's why you want to add them to your watchlist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1d784bb9fed5ec33b1ed889f22ffb6b4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>1. Abbott Laboratories</h2>\n<p><b>Abbott Laboratories</b> (NYSE:ABT) shares have gained around 26% in 2021. At recent prices, the stock offers an anemic 1.4% dividend yield.</p>\n<p>Patient investors who've held shares of this Dividend Aristocrat have seen their quarterly payments rise 77% over the past five years. Despite the big payout bumps, Abbott only needed around 33% of the free cash flow its operations generated over the past year to make dividend payments. That means the company shouldn't have any trouble raising the payout in line with earnings growth in the foreseeable future.</p>\n<p>Abbott is a healthcare conglomerate that makes most of its money selling medical devices and diagnostics. Its medical-device segment is under some pressure due to COVID-19 because it takes a lot of doctor visits before patients can receive a new pacemaker or a replacement heart valve. Despite pandemic pressure, medical-device segment sales during the first nine months of 2021 rose 24.5% year over year to $10.6 billion.</p>\n<p>Diagnostics sales in the first nine months of 2021 soared a whopping 73% year over year to $11.2 billion. Soaring demand for COVID-19 tests isn't good news for the medical-device segment, but improved diagnostics sales more than make up the difference.</p>\n<p>It's been over 50 years since Abbott went a whole year without raising its dividend payout. Considering the company's well-diversified operation, investors can reasonably expect their payouts to keep rising for another decade or two.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/df00d3dd1509e35f75cdcc720ed18995\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>2. AbbVie</h2>\n<p>The second half of 2021 has been disastrous for most drugmaker stocks, but not <b>AbbVie</b> (NYSE:ABBV). Shares of the pharmaceutical giant are up more than 22% this year. Since spinning off from Abbott Laboratories in 2013, the stock has risen around 271%, but that's not the whole story. Once you factor in steadily rising dividend payments, investors who held on to their shares have already received a 438% total return since the beginning of 2013.</p>\n<p>Over the past eight years, AbbVie's dividend has risen a whopping 253%, and at recent prices, the stock offers a tempting 4.3% yield. Despite the rapid raises, the company needed just 42% of free cash flow generated over the past year to meet its rapidly rising dividend obligation.</p>\n<p>AbbVie has offered an above-average dividend since its inception because investors are rightfully nervous about the company's ability to keep raising it in the long run. This company's largest source of revenue, Humira, is also the world's top-selling drug, with sales that rose 5.6% year over year in the third quarter up to an annualized $21.7 billion.</p>\n<p>Humira lost market exclusivity in the EU in 2018, and now 85% of its sales come from the U.S. market. In about a year, biosimilar versions of Humira that are already approved by the Food and Drug Administration (FDA) are expected to finally begin hammering Humira sales into the dirt.</p>\n<p>A few years ago, Humira's demise would have been disastrous for AbbVie, but the company's done an outstanding job at using Humira cash flows to license, acquire, and develop new blockbuster drugs that will more than offset the losses. Third-quarter sales of Rinvoq, a once-daily pill for the treatment of rheumatoid arthritis that AbbVie launched in 2019, more than doubled year over year to an annualized $1.8 billion. Sales of Skyrizi, a psoriasis drug also launched in 2019, soared 83.3% year over year to an annualized $3.2 billion.</p>\n<p>The Botox brand of injectable botulinum toxin is far more resilient to the loss of exclusivity issues facing Humira because it isn't exactly exclusive in the first place. Cosmetic Botox is more popular than ever, with third-quarter sales that soared 39% year over year to an annualized $2.2 billion. Therapeutic Botox sales rose 23% year over year to an annualized $2.6 billion.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a38a39e3008a5ed3fc1899ce26a04cb1\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>3. Johnson & Johnson</h2>\n<p><b>Johnson & Johnson</b> (NYSE:JNJ) shares haven't performed as well as Abbott's or AbbVie's this year. Slow-growing sales of consumer-health products like Q-tips and Band-Aids have finally pushed the company to spin off its consumer-health segment into a new company.</p>\n<p>You probably want to wait for the dips with Johnson & Johnson because at recent prices, the stock offers an uninspiring 2.5% yield. Once the company splits in two, shareholders will receive two quarterly payouts that should add up to the same amount they were receiving before the spin-off, or even more.</p>\n<p>Johnson & Johnson has raised its dividend every year for 60 straight years. Over the past five years, the payout has risen by 32.5%, which isn't amazing but more than enough to outpace inflation.</p>\n<p>While I'm not expecting a great deal of growth from the new consumer-health business, Johnson & Johnson's pharmaceutical division is firing on all cylinders. While the company's COVID-19 vaccine gets the most attention, it's not a very important part of the company's overall pharmaceutical business.</p>\n<p>Johnson & Johnson's total pharmaceutical sales in the third quarter rose 13.8% year over year. A new psoriasis drug called Tremfya and a cancer therapy called Darzalex provided most of the growth. With the company's new products leading the way, investors can look forward to a steadily growing dividend payout for many years to come.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy If the Market Crashes in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy If the Market Crashes in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 11:06 GMT+8 <a href=https://www.fool.com/investing/2021/12/26/3-dividend-stocks-to-buy-if-market-crashes-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Market crashes happen, and they tend to drag down the best stocks along with the rest of the market. It's impossible to predict the timing and severity of the next downturn, but it's easy to imagine ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/26/3-dividend-stocks-to-buy-if-market-crashes-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4559":"巴菲特持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","JNJ":"强生","ABBV":"艾伯维公司","BK4566":"资本集团","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","ABT":"雅培"},"source_url":"https://www.fool.com/investing/2021/12/26/3-dividend-stocks-to-buy-if-market-crashes-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194717735","content_text":"Market crashes happen, and they tend to drag down the best stocks along with the rest of the market. It's impossible to predict the timing and severity of the next downturn, but it's easy to imagine one occurring in the near term.\nThe omicron variant keeps threatening to pinch the global economy. If the latest variant of concern quickly fizzles out, rising inflation could prompt the Federal Reserve to raise interest rates.\nThese three companies make reliable dividend payments in good times and bad. Their stocks are up near 52-week highs at the moment, but an overall market downturn could push them down to highly attractive prices. Here's why you want to add them to your watchlist.\nImage source: Getty Images.\n1. Abbott Laboratories\nAbbott Laboratories (NYSE:ABT) shares have gained around 26% in 2021. At recent prices, the stock offers an anemic 1.4% dividend yield.\nPatient investors who've held shares of this Dividend Aristocrat have seen their quarterly payments rise 77% over the past five years. Despite the big payout bumps, Abbott only needed around 33% of the free cash flow its operations generated over the past year to make dividend payments. That means the company shouldn't have any trouble raising the payout in line with earnings growth in the foreseeable future.\nAbbott is a healthcare conglomerate that makes most of its money selling medical devices and diagnostics. Its medical-device segment is under some pressure due to COVID-19 because it takes a lot of doctor visits before patients can receive a new pacemaker or a replacement heart valve. Despite pandemic pressure, medical-device segment sales during the first nine months of 2021 rose 24.5% year over year to $10.6 billion.\nDiagnostics sales in the first nine months of 2021 soared a whopping 73% year over year to $11.2 billion. Soaring demand for COVID-19 tests isn't good news for the medical-device segment, but improved diagnostics sales more than make up the difference.\nIt's been over 50 years since Abbott went a whole year without raising its dividend payout. Considering the company's well-diversified operation, investors can reasonably expect their payouts to keep rising for another decade or two.\nImage source: Getty Images.\n2. AbbVie\nThe second half of 2021 has been disastrous for most drugmaker stocks, but not AbbVie (NYSE:ABBV). Shares of the pharmaceutical giant are up more than 22% this year. Since spinning off from Abbott Laboratories in 2013, the stock has risen around 271%, but that's not the whole story. Once you factor in steadily rising dividend payments, investors who held on to their shares have already received a 438% total return since the beginning of 2013.\nOver the past eight years, AbbVie's dividend has risen a whopping 253%, and at recent prices, the stock offers a tempting 4.3% yield. Despite the rapid raises, the company needed just 42% of free cash flow generated over the past year to meet its rapidly rising dividend obligation.\nAbbVie has offered an above-average dividend since its inception because investors are rightfully nervous about the company's ability to keep raising it in the long run. This company's largest source of revenue, Humira, is also the world's top-selling drug, with sales that rose 5.6% year over year in the third quarter up to an annualized $21.7 billion.\nHumira lost market exclusivity in the EU in 2018, and now 85% of its sales come from the U.S. market. In about a year, biosimilar versions of Humira that are already approved by the Food and Drug Administration (FDA) are expected to finally begin hammering Humira sales into the dirt.\nA few years ago, Humira's demise would have been disastrous for AbbVie, but the company's done an outstanding job at using Humira cash flows to license, acquire, and develop new blockbuster drugs that will more than offset the losses. Third-quarter sales of Rinvoq, a once-daily pill for the treatment of rheumatoid arthritis that AbbVie launched in 2019, more than doubled year over year to an annualized $1.8 billion. Sales of Skyrizi, a psoriasis drug also launched in 2019, soared 83.3% year over year to an annualized $3.2 billion.\nThe Botox brand of injectable botulinum toxin is far more resilient to the loss of exclusivity issues facing Humira because it isn't exactly exclusive in the first place. Cosmetic Botox is more popular than ever, with third-quarter sales that soared 39% year over year to an annualized $2.2 billion. Therapeutic Botox sales rose 23% year over year to an annualized $2.6 billion.\nImage source: Getty Images.\n3. Johnson & Johnson\nJohnson & Johnson (NYSE:JNJ) shares haven't performed as well as Abbott's or AbbVie's this year. Slow-growing sales of consumer-health products like Q-tips and Band-Aids have finally pushed the company to spin off its consumer-health segment into a new company.\nYou probably want to wait for the dips with Johnson & Johnson because at recent prices, the stock offers an uninspiring 2.5% yield. Once the company splits in two, shareholders will receive two quarterly payouts that should add up to the same amount they were receiving before the spin-off, or even more.\nJohnson & Johnson has raised its dividend every year for 60 straight years. Over the past five years, the payout has risen by 32.5%, which isn't amazing but more than enough to outpace inflation.\nWhile I'm not expecting a great deal of growth from the new consumer-health business, Johnson & Johnson's pharmaceutical division is firing on all cylinders. While the company's COVID-19 vaccine gets the most attention, it's not a very important part of the company's overall pharmaceutical business.\nJohnson & Johnson's total pharmaceutical sales in the third quarter rose 13.8% year over year. A new psoriasis drug called Tremfya and a cancer therapy called Darzalex provided most of the growth. With the company's new products leading the way, investors can look forward to a steadily growing dividend payout for many years to come.","news_type":1,"symbols_score_info":{"ABBV":0.9,"ABT":0.9,"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":2156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698410436,"gmtCreate":1640489475067,"gmtModify":1640489475263,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698410436","repostId":"2193033173","repostType":4,"repost":{"id":"2193033173","kind":"highlight","pubTimestamp":1640485471,"share":"https://ttm.financial/m/news/2193033173?lang=&edition=full","pubTime":"2021-12-26 10:24","market":"us","language":"en","title":"3 Stocking Stuffer Stocks You Can Buy for Less Than $10 Apiece","url":"https://stock-news.laohu8.com/highlight/detail?id=2193033173","media":"Motley Fool","summary":"If you're looking for last-minute holiday deals for your portfolio, here are three growing companies trading in the single digits.","content":"<p>Everyone likes to check their stockings over the holidays to see if any small gifts found their way inside. They naturally have to be compact presents to fit in a Christmas stocking, but sometimes, the best things come from the smallest of packages. It could be the same with stocks.</p>\n<p><b>Sirius XM Holdings </b>(NASDAQ:SIRI), <b>Latch</b> (NASDAQ:LTCH), and <b>Genius Sports</b> (NYSE:GENI) all trade in the single digits, but they have the potential to make outsized gains in the year ahead. Stocks in socks? Let's see why these three stocks under $10 would make ideal stocking stuffers for your portfolio this season.</p>\n<h2>Sirius XM Holdings</h2>\n<p>The satellite-radio provider has come a long way since it was on the brink of bankruptcy a dozen years ago. Sirius XM has emerged as a slow yet steady grower that's consistently profitable as it generates a ton of free cash flow. Closing out its latest quarter with 32 million self-pay subscribers on its platform, Sirius XM has defied the skeptics that figured folks would abandon satellite radio-subscriptions, as connected cars now have access to cheaper audio solutions.</p>\n<p>Revenue rose a better-than-expected 9% to $2.2 billion in the third quarter. A 32% surge in ad revenue for its Pandora streaming service helped lift the 5% increase in its original satellite-radio business, but it all fits the \"slow yet steady\" narrative. Net income is growing even faster, and Sirius XM now expects to generate $1.8 billion in free cash flow this year.</p>\n<p>Sirius XM isn't afraid to return money to its shareholders. It's been aggressively buying back shares. It also boosted its dividend since initiating a payout policy in 2016, including a 50% hike for its quarterly rate two months ago.</p>\n<h2>Latch</h2>\n<p>One of this year's more interesting debutantes is Latch, a company that's revolutionizing the way apartment landlords and tenants access their digs. LatchOS is an operating system that allows folks to remotely open and close their front doors. It's simple, in theory, but don't dismiss this as a limited studio apartment without a lot of room to grow.</p>\n<p>Cloud-based access solutions make it easy for landlords or realtors to show an available property without having to physically be there. The high-tech keyless platform also helps building owners move tenants in and out without having to collect physical keys and bring in a locksmith to change out the locks. Renters also benefit from the ability to let in houseguests, a cleaning service, or perhaps even a delivery when they're not home. More than 1 in 10 new apartment buildings are now being constructed incorporating LatchOS into their premium designs.</p>\n<p>This isn't a one-lock pony. Latch and landlords can also upsell the platform so it works with intercom systems and smart-home hubs. Growth is pretty impressive, with revenue up 120% in its latest quarter. The pipeline is even more exciting, with total bookings soaring 181%.</p>\n<p>Latch is small. Its guidance calls for roughly $40 million in revenue this year, and its market cap is just $1.1 billion. Growth should be explosive for the next few years, making this a bargain that's trading for less than its debut earlier this year as a special purpose acquisition company.</p>\n<h2>Genius Sports</h2>\n<p>There's a lot of money being spent to make sure that sports statistics are accurate and delivered promptly, and Genius Sports is a leader in this niche. It provides data and software solutions for the sportsbook and media industries, as gamblers and journalists need official scores and stats in a timely manner. Individual leagues and teams also turn to Genius to help them collect, analyze, and monetize data and live video.</p>\n<p>Genius has more than 700 long-term partnerships in place, and one of them is the NFL. More than 97% of the U.S. market uses NFL data provided through Genius Sports.</p>\n<p>It's not the only player in this market, but it's growing quickly. Revenue rose 70% in its latest quarter. The bottom line will take some time to get going, but for now, it's scoring more-than-enough points to win the Wall Street game in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocking Stuffer Stocks You Can Buy for Less Than $10 Apiece</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocking Stuffer Stocks You Can Buy for Less Than $10 Apiece\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:24 GMT+8 <a href=https://www.fool.com/investing/2021/12/24/3-stocking-stuffer-stocks-you-can-buy-for-less-tha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Everyone likes to check their stockings over the holidays to see if any small gifts found their way inside. They naturally have to be compact presents to fit in a Christmas stocking, but sometimes, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-stocking-stuffer-stocks-you-can-buy-for-less-tha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LTCH":"Latch, Inc.","SIRI":"Sirius XM Holdings Inc.","GENI":"Genius Sports Ltd","BK4023":"应用软件","BK4559":"巴菲特持仓","BK4100":"有线和卫星","BK4077":"互动媒体与服务"},"source_url":"https://www.fool.com/investing/2021/12/24/3-stocking-stuffer-stocks-you-can-buy-for-less-tha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193033173","content_text":"Everyone likes to check their stockings over the holidays to see if any small gifts found their way inside. They naturally have to be compact presents to fit in a Christmas stocking, but sometimes, the best things come from the smallest of packages. It could be the same with stocks.\nSirius XM Holdings (NASDAQ:SIRI), Latch (NASDAQ:LTCH), and Genius Sports (NYSE:GENI) all trade in the single digits, but they have the potential to make outsized gains in the year ahead. Stocks in socks? Let's see why these three stocks under $10 would make ideal stocking stuffers for your portfolio this season.\nSirius XM Holdings\nThe satellite-radio provider has come a long way since it was on the brink of bankruptcy a dozen years ago. Sirius XM has emerged as a slow yet steady grower that's consistently profitable as it generates a ton of free cash flow. Closing out its latest quarter with 32 million self-pay subscribers on its platform, Sirius XM has defied the skeptics that figured folks would abandon satellite radio-subscriptions, as connected cars now have access to cheaper audio solutions.\nRevenue rose a better-than-expected 9% to $2.2 billion in the third quarter. A 32% surge in ad revenue for its Pandora streaming service helped lift the 5% increase in its original satellite-radio business, but it all fits the \"slow yet steady\" narrative. Net income is growing even faster, and Sirius XM now expects to generate $1.8 billion in free cash flow this year.\nSirius XM isn't afraid to return money to its shareholders. It's been aggressively buying back shares. It also boosted its dividend since initiating a payout policy in 2016, including a 50% hike for its quarterly rate two months ago.\nLatch\nOne of this year's more interesting debutantes is Latch, a company that's revolutionizing the way apartment landlords and tenants access their digs. LatchOS is an operating system that allows folks to remotely open and close their front doors. It's simple, in theory, but don't dismiss this as a limited studio apartment without a lot of room to grow.\nCloud-based access solutions make it easy for landlords or realtors to show an available property without having to physically be there. The high-tech keyless platform also helps building owners move tenants in and out without having to collect physical keys and bring in a locksmith to change out the locks. Renters also benefit from the ability to let in houseguests, a cleaning service, or perhaps even a delivery when they're not home. More than 1 in 10 new apartment buildings are now being constructed incorporating LatchOS into their premium designs.\nThis isn't a one-lock pony. Latch and landlords can also upsell the platform so it works with intercom systems and smart-home hubs. Growth is pretty impressive, with revenue up 120% in its latest quarter. The pipeline is even more exciting, with total bookings soaring 181%.\nLatch is small. Its guidance calls for roughly $40 million in revenue this year, and its market cap is just $1.1 billion. Growth should be explosive for the next few years, making this a bargain that's trading for less than its debut earlier this year as a special purpose acquisition company.\nGenius Sports\nThere's a lot of money being spent to make sure that sports statistics are accurate and delivered promptly, and Genius Sports is a leader in this niche. It provides data and software solutions for the sportsbook and media industries, as gamblers and journalists need official scores and stats in a timely manner. Individual leagues and teams also turn to Genius to help them collect, analyze, and monetize data and live video.\nGenius has more than 700 long-term partnerships in place, and one of them is the NFL. More than 97% of the U.S. market uses NFL data provided through Genius Sports.\nIt's not the only player in this market, but it's growing quickly. Revenue rose 70% in its latest quarter. The bottom line will take some time to get going, but for now, it's scoring more-than-enough points to win the Wall Street game in 2022.","news_type":1,"symbols_score_info":{"GENI":0.9,"LTCH":0.9,"SIRI":0.9}},"isVote":1,"tweetType":1,"viewCount":1665,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698233096,"gmtCreate":1640400861121,"gmtModify":1640400861395,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698233096","repostId":"2193317305","repostType":4,"repost":{"id":"2193317305","kind":"highlight","pubTimestamp":1640399660,"share":"https://ttm.financial/m/news/2193317305?lang=&edition=full","pubTime":"2021-12-25 10:34","market":"us","language":"en","title":"Can This Top Blue Chip Stock Handle Soaring Inflation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2193317305","media":"Motley Fool","summary":"We are in strange times right now, so how companies navigate the current environment is vital to their success.","content":"<p>In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was the highest increase in almost 40 years. </p>\n<p>For a company like <b>Home Depot</b> (NYSE:HD) that has done extremely well during the pandemic, the threat of rising costs is a real challenge heading into the new year, having possibly negative implications ahead of what is traditionally a busy spring and summer for the business. </p>\n<p>Continue reading to find out how this blue chip stock is dealing with the current situation. </p>\n<h2>Lumber prices are going back up </h2>\n<p>A major commodity that has a meaningful impact on Home Depot's business is lumber. From April 2020 to May 2021, lumber prices skyrocketed to nearly $1,700 per thousand board feet, an all-time record. Prices came down over the following few months, but they shot up again from mid-November to mid-December, settling at just over $1,000 per thousand board feet today. This is still extremely high from a historical perspective. </p>\n<p>\"Lumber is a driver of projects throughout the business, and that certainly carries on,\" Chief Executive Officer Craig Menear highlighted on the company's third-quarter earnings call. During Home Depot's fiscal second quarter that ended Aug. 1 (when lumber prices were sky-high), the company posted record quarterly sales of $41.1 billion. The gross margin of 33.2%, while down slightly from previous quarters, was still very healthy and in line with past results. </p>\n<p>This is a positive indicator of Home Depot's ability to handle the unpredictable price swings with a core commodity like lumber. As prices soared, unit sales fell. Even so, the business reported a historic quarter. Now, as lumber prices rise, especially ahead of the busy home-building and remodeling season in the spring and summer, don't be surprised if lumber unit sales start to drop again. </p>\n<p>Nonetheless, other product categories like outdoor garden, appliances, and kitchen and bath should be strong. And thanks to a robust housing market, characterized by low interest rates, consumers are increasingly looking to undertake renovation projects to boost the value of their existing homes. This underlying trend supports demand for the products and services Home Depot offers. </p>\n<p>\"We have effectively managed inflationary environments in the past, and we feel good about our ability to continue managing through the current environment,\" said President and Chief Operating Officer Ted Decker on the latest conference call with Wall Street analysts.</p>\n<h2>Home Depot's success is undeniable </h2>\n<p>One of Home Depot's overarching objectives is to be the low-cost provider in the home improvement industry. This means that the business wants to lag competitors when raising prices and lead when reducing prices. Obviously, this negatively impacts profitability in the near term as the company is hesitant to pass higher costs on to consumers. </p>\n<p>But if we look at Home Depot's historical performance, we see that this is definitely the right strategy to take. Over the past several years, while revenue has grown in the mid-single digits on a yearly basis, net income has soared as a result of expanding margins. In fiscal 2015, profit totaled $7 billion. Over the trailing-12-month period, it was almost $16 billion. </p>\n<p>And the business is popular among contractors and other professionals, who account for roughly 45% of sales. Instead of immediately passing on higher input costs, which could alienate these high-value customers and push them to competitors, Home Depot understands that building long-term relationships with them is crucial to the success of the company. Sacrificing margin in unusual times like today to keep customers loyal is the right move. </p>\n<p>The current economic environment is full of uncertainties with issues like the omicron coronavirus variant and tightening monetary policy receiving the bulk of investors' attention. When it comes to inflation in particular, I have no reason to believe that Home Depot won't be able to step up to whatever challenges 2022 brings. </p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can This Top Blue Chip Stock Handle Soaring Inflation?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan This Top Blue Chip Stock Handle Soaring Inflation?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:34 GMT+8 <a href=https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4566":"资本集团","BK4083":"家庭装潢零售","BK4550":"红杉资本持仓","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","HD":"家得宝","BK4533":"AQR资本管理(全球第二大对冲基金)"},"source_url":"https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193317305","content_text":"In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was the highest increase in almost 40 years. \nFor a company like Home Depot (NYSE:HD) that has done extremely well during the pandemic, the threat of rising costs is a real challenge heading into the new year, having possibly negative implications ahead of what is traditionally a busy spring and summer for the business. \nContinue reading to find out how this blue chip stock is dealing with the current situation. \nLumber prices are going back up \nA major commodity that has a meaningful impact on Home Depot's business is lumber. From April 2020 to May 2021, lumber prices skyrocketed to nearly $1,700 per thousand board feet, an all-time record. Prices came down over the following few months, but they shot up again from mid-November to mid-December, settling at just over $1,000 per thousand board feet today. This is still extremely high from a historical perspective. \n\"Lumber is a driver of projects throughout the business, and that certainly carries on,\" Chief Executive Officer Craig Menear highlighted on the company's third-quarter earnings call. During Home Depot's fiscal second quarter that ended Aug. 1 (when lumber prices were sky-high), the company posted record quarterly sales of $41.1 billion. The gross margin of 33.2%, while down slightly from previous quarters, was still very healthy and in line with past results. \nThis is a positive indicator of Home Depot's ability to handle the unpredictable price swings with a core commodity like lumber. As prices soared, unit sales fell. Even so, the business reported a historic quarter. Now, as lumber prices rise, especially ahead of the busy home-building and remodeling season in the spring and summer, don't be surprised if lumber unit sales start to drop again. \nNonetheless, other product categories like outdoor garden, appliances, and kitchen and bath should be strong. And thanks to a robust housing market, characterized by low interest rates, consumers are increasingly looking to undertake renovation projects to boost the value of their existing homes. This underlying trend supports demand for the products and services Home Depot offers. \n\"We have effectively managed inflationary environments in the past, and we feel good about our ability to continue managing through the current environment,\" said President and Chief Operating Officer Ted Decker on the latest conference call with Wall Street analysts.\nHome Depot's success is undeniable \nOne of Home Depot's overarching objectives is to be the low-cost provider in the home improvement industry. This means that the business wants to lag competitors when raising prices and lead when reducing prices. Obviously, this negatively impacts profitability in the near term as the company is hesitant to pass higher costs on to consumers. \nBut if we look at Home Depot's historical performance, we see that this is definitely the right strategy to take. Over the past several years, while revenue has grown in the mid-single digits on a yearly basis, net income has soared as a result of expanding margins. In fiscal 2015, profit totaled $7 billion. Over the trailing-12-month period, it was almost $16 billion. \nAnd the business is popular among contractors and other professionals, who account for roughly 45% of sales. Instead of immediately passing on higher input costs, which could alienate these high-value customers and push them to competitors, Home Depot understands that building long-term relationships with them is crucial to the success of the company. Sacrificing margin in unusual times like today to keep customers loyal is the right move. \nThe current economic environment is full of uncertainties with issues like the omicron coronavirus variant and tightening monetary policy receiving the bulk of investors' attention. When it comes to inflation in particular, I have no reason to believe that Home Depot won't be able to step up to whatever challenges 2022 brings.","news_type":1,"symbols_score_info":{"HD":0.9}},"isVote":1,"tweetType":1,"viewCount":1853,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698875838,"gmtCreate":1640354691427,"gmtModify":1640354781133,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698875838","repostId":"1175608113","repostType":4,"repost":{"id":"1175608113","kind":"news","pubTimestamp":1640342686,"share":"https://ttm.financial/m/news/1175608113?lang=&edition=full","pubTime":"2021-12-24 18:44","market":"us","language":"en","title":"Is Amazon Stock A Buy Right Now As Epic Battle With Walmart Escalates","url":"https://stock-news.laohu8.com/highlight/detail?id=1175608113","media":"Investors","summary":"Amazon(AMZN) plans to build its first large-format retail stores, making a new foray into physical o","content":"<p><b>Amazon</b>(AMZN) plans to build its first large-format retail stores, making a new foray into physical outlets and stepping up its battle against <b>Walmart</b>(WMT). Is Amazon stock a buy?</p>\n<p>Amazon's 30,000-square-foot stores, which will debut in California and Ohio, are less than one-third the size of Walmart's conventional outlets. They're about one-sixth the size of Walmart Supercenter stores.</p>\n<p>Walmart, the behemoth of brick-and-mortar discount stores, is dueling Amazon, the giant of online shopping, in a battle over the future of retail, e-commerce and grocery shopping.</p>\n<p>Much work remains for either company to win theAmazon vs. Walmart battle. Walmart needs to expand online operations while also managing 11,500 stores across 28 countries, of which 4,743 are in the U.S. It's in the process of redesigning 1,000 stores by the end of 2021. Its goal is to create a more streamlined and faster shopping experience for customers.</p>\n<p>At the same time, Amazon must continue its aggressive rollout of warehouse distribution centers and figure out its strategy for building physical stores.</p>\n<p>Amazon Is Making Critical Investments</p>\n<p>\"The key question from here is when/if does the current investment cycle drive evidence of share gains and margin leverage,\" RBC Capital Markets analyst Brad Erickson said in a note. \"Only time will tell, but in our view AMZN stock is making critical investments as consumers increasingly demand faster shipping which should at least maintain share gains while, importantly, growing gross profit dollars.\"</p>\n<p>Amazon reported third-quarter results on Oct. 28. Adjusted earnings fell 51% from the year-ago period to $6.12 a share. Analysts expected $8.92 a share. Revenue climbed 15% to $110.8 billion, below expectations of $111.6 billion.</p>\n<p>For its fourth quarter, Amazon forecast revenue in the range of $130 billion to $140 billion. That missed analyst estimates for $142 billion. Amazon forecast earnings before interest and taxes, called EBIT, of $1.5 billion, versus estimates of $8.1 billion.</p>\n<p>The company's cloud-computing unit, Amazon Web Services, reported revenue growth of 39% to $11.6 billion. That topped estimates for 35% cloud-computing growth.</p>\n<p>Cowen analyst John Blackledge recently raised his price target on Amazon stock to 4,500, from 4,300. He listed Amazon as one of the \"best ideas\" for 2022, in the mega-cap category.</p>\n<p><b>Amazon Introduces Numerous New Gadgets</b></p>\n<p>On Sept. 28, Amazon introduced aplethora of consumer electronics gadgets, including smart displays and a home robot, at a fall product launch event.</p>\n<p>The Seattle-based e-commerce giant unveiled several devices that leverage its Alexa voice assistant technology. They include theEcho Show 15smart display, which is designed to keep families organized, connected and entertained.</p>\n<p>Another Alexa-enabled device is Amazon's first robot, which is named Astro. The robot will act as a security guard, companion and mobile smart display. It brings together new advancements in artificial intelligence, computer vision, sensor technology, and voice and edge computing, the company said.</p>\n<p>Earlier this month, Amazon moved deeper into the television market with an all-new lineup of devices and its first Amazon-branded 4K smart TVs. The Amazon TV products go on sale in October. Amazon also introduced a 4K version of its Fire TV stick.</p>\n<p><b>Plenty Of Growth Opportunities</b></p>\n<p>Amazon entered 2021 with plenty of big growth opportunities. This included plans to expand its virtual health care program across the U.S. It is also expanding its prescription drug business.</p>\n<p>On March 17, Amazon announced that its telehealth pilot program, called Amazon Care, would expand to all of its U.S. employees and their families as well as other firms this summer. The program first launched at its Seattle headquarters 18 months ago.</p>\n<p>If Amazon can deliver more efficient health care services, the potential is enormous for fueling its growth engine — and by extension Amazon stock. Health care now comprises nearly a fifth of the U.S. economy.</p>\n<p>Amazon said the program enables workers to connect with medical professionals via chat or video conference, and connect patients with medical professionals. In addition, Amazon Care can dispatch a medical professional to a patient's home for additional care.</p>\n<p>Analysts at Jefferies give Amazon a buy rating and price target or 4,000.</p>\n<p>\"We believe low expectations following two consecutive guide-downs better positions AMZN for upside in the core retail business,\" according to a Jefferies report.</p>\n<p>\"We also see attractive growth at AWS and advertising, AMZN's two highest margin businesses, serving to more than offset near-term cost headwinds from labor shortages and supply chain disruption,\" it said.</p>\n<p><b>Tapping The Market For Prescription Drugs</b></p>\n<p>In addition, Amazon is tapping into the $350 billion market for prescription drugs. The company fired a big shot across the bow of drugstores and prescription drug wholesalers late last year when it launched Amazon Pharmacy. The new unit will offer Amazon Prime members discounts of up to 80% on generic drugs and 40% on brand medications.</p>\n<p>On May 26, Amazon announced it is acquiring iconic film studio Metro-Goldwyn-Mayer for $8.45 billion, looking broadly expand its position in streaming video and increase the value of its Prime rewards program. The acquisition is Amazon's largest since buying Whole Foods for $13.7 billion in 2017.</p>\n<p>To get Amazon Prime, users pay an annual or monthly fee for the service and receive multiple perks. This includes free access to Amazon Video and Amazon Music. Amazon has invested billions of dollars in its film and TV operations as well as live sports.</p>\n<p>Another growth vehicle for Amazon in 2021 is advertising. When looking for a product, about half of U.S. adults start their search with Amazon. More searches draw more advertisers. And as Covid-19 has caused more consumers to shop online that will keep Amazon's ad growth humming.</p>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Amazon Stock A Buy Right Now As Epic Battle With Walmart Escalates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Amazon Stock A Buy Right Now As Epic Battle With Walmart Escalates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 18:44 GMT+8 <a href=https://www.investors.com/news/technology/amazon-stock-buy-now/?src=A00220><strong>Investors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon(AMZN) plans to build its first large-format retail stores, making a new foray into physical outlets and stepping up its battle against Walmart(WMT). Is Amazon stock a buy?\nAmazon's 30,000-...</p>\n\n<a href=\"https://www.investors.com/news/technology/amazon-stock-buy-now/?src=A00220\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WMT":"沃尔玛","AMZN":"亚马逊"},"source_url":"https://www.investors.com/news/technology/amazon-stock-buy-now/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175608113","content_text":"Amazon(AMZN) plans to build its first large-format retail stores, making a new foray into physical outlets and stepping up its battle against Walmart(WMT). Is Amazon stock a buy?\nAmazon's 30,000-square-foot stores, which will debut in California and Ohio, are less than one-third the size of Walmart's conventional outlets. They're about one-sixth the size of Walmart Supercenter stores.\nWalmart, the behemoth of brick-and-mortar discount stores, is dueling Amazon, the giant of online shopping, in a battle over the future of retail, e-commerce and grocery shopping.\nMuch work remains for either company to win theAmazon vs. Walmart battle. Walmart needs to expand online operations while also managing 11,500 stores across 28 countries, of which 4,743 are in the U.S. It's in the process of redesigning 1,000 stores by the end of 2021. Its goal is to create a more streamlined and faster shopping experience for customers.\nAt the same time, Amazon must continue its aggressive rollout of warehouse distribution centers and figure out its strategy for building physical stores.\nAmazon Is Making Critical Investments\n\"The key question from here is when/if does the current investment cycle drive evidence of share gains and margin leverage,\" RBC Capital Markets analyst Brad Erickson said in a note. \"Only time will tell, but in our view AMZN stock is making critical investments as consumers increasingly demand faster shipping which should at least maintain share gains while, importantly, growing gross profit dollars.\"\nAmazon reported third-quarter results on Oct. 28. Adjusted earnings fell 51% from the year-ago period to $6.12 a share. Analysts expected $8.92 a share. Revenue climbed 15% to $110.8 billion, below expectations of $111.6 billion.\nFor its fourth quarter, Amazon forecast revenue in the range of $130 billion to $140 billion. That missed analyst estimates for $142 billion. Amazon forecast earnings before interest and taxes, called EBIT, of $1.5 billion, versus estimates of $8.1 billion.\nThe company's cloud-computing unit, Amazon Web Services, reported revenue growth of 39% to $11.6 billion. That topped estimates for 35% cloud-computing growth.\nCowen analyst John Blackledge recently raised his price target on Amazon stock to 4,500, from 4,300. He listed Amazon as one of the \"best ideas\" for 2022, in the mega-cap category.\nAmazon Introduces Numerous New Gadgets\nOn Sept. 28, Amazon introduced aplethora of consumer electronics gadgets, including smart displays and a home robot, at a fall product launch event.\nThe Seattle-based e-commerce giant unveiled several devices that leverage its Alexa voice assistant technology. They include theEcho Show 15smart display, which is designed to keep families organized, connected and entertained.\nAnother Alexa-enabled device is Amazon's first robot, which is named Astro. The robot will act as a security guard, companion and mobile smart display. It brings together new advancements in artificial intelligence, computer vision, sensor technology, and voice and edge computing, the company said.\nEarlier this month, Amazon moved deeper into the television market with an all-new lineup of devices and its first Amazon-branded 4K smart TVs. The Amazon TV products go on sale in October. Amazon also introduced a 4K version of its Fire TV stick.\nPlenty Of Growth Opportunities\nAmazon entered 2021 with plenty of big growth opportunities. This included plans to expand its virtual health care program across the U.S. It is also expanding its prescription drug business.\nOn March 17, Amazon announced that its telehealth pilot program, called Amazon Care, would expand to all of its U.S. employees and their families as well as other firms this summer. The program first launched at its Seattle headquarters 18 months ago.\nIf Amazon can deliver more efficient health care services, the potential is enormous for fueling its growth engine — and by extension Amazon stock. Health care now comprises nearly a fifth of the U.S. economy.\nAmazon said the program enables workers to connect with medical professionals via chat or video conference, and connect patients with medical professionals. In addition, Amazon Care can dispatch a medical professional to a patient's home for additional care.\nAnalysts at Jefferies give Amazon a buy rating and price target or 4,000.\n\"We believe low expectations following two consecutive guide-downs better positions AMZN for upside in the core retail business,\" according to a Jefferies report.\n\"We also see attractive growth at AWS and advertising, AMZN's two highest margin businesses, serving to more than offset near-term cost headwinds from labor shortages and supply chain disruption,\" it said.\nTapping The Market For Prescription Drugs\nIn addition, Amazon is tapping into the $350 billion market for prescription drugs. The company fired a big shot across the bow of drugstores and prescription drug wholesalers late last year when it launched Amazon Pharmacy. The new unit will offer Amazon Prime members discounts of up to 80% on generic drugs and 40% on brand medications.\nOn May 26, Amazon announced it is acquiring iconic film studio Metro-Goldwyn-Mayer for $8.45 billion, looking broadly expand its position in streaming video and increase the value of its Prime rewards program. The acquisition is Amazon's largest since buying Whole Foods for $13.7 billion in 2017.\nTo get Amazon Prime, users pay an annual or monthly fee for the service and receive multiple perks. This includes free access to Amazon Video and Amazon Music. Amazon has invested billions of dollars in its film and TV operations as well as live sports.\nAnother growth vehicle for Amazon in 2021 is advertising. When looking for a product, about half of U.S. adults start their search with Amazon. More searches draw more advertisers. And as Covid-19 has caused more consumers to shop online that will keep Amazon's ad growth humming.","news_type":1,"symbols_score_info":{"AMZN":0.9,"WMT":0.9}},"isVote":1,"tweetType":1,"viewCount":1503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698086345,"gmtCreate":1640262495042,"gmtModify":1640262495230,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698086345","repostId":"1187215359","repostType":4,"repost":{"id":"1187215359","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640260771,"share":"https://ttm.financial/m/news/1187215359?lang=&edition=full","pubTime":"2021-12-23 19:59","market":"us","language":"en","title":"Cathie Wood Loads Up Another $800K In This Chinese Tesla Rival Ahead Of Its Overseas Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1187215359","media":"Benzinga","summary":"Cathie Wood’s Ark Investment Management on Friday loaded up another 18,000 shares — worth about $823","content":"<p><b>Cathie Wood</b>’s <b>Ark Investment Management</b> on Friday loaded up another 18,000 shares — worth about $823,320 — in the U.S. listed Chinese electric vehicle maker <b>Xpeng Inc</b>(NYSE:XPEV).</p>\n<p>Xpeng’s stock closed 4.5% higher at $44.47 a share on Wednesday. The stock is up about 3.7% fp or the year.</p>\n<p>The Guangzhou, China-based company bolted ahead of local rivals Nio and <b>Li Auto Inc</b>(NASDAQ:LI) last month with deliveries.</p>\n<p>Each of the three players delivered more than 10,000 electric vehicles — with Xpeng leading the pack at 15,613 units, Li Auto grabbing the second spot at 13,485 units and Nio dispatching 10,878 units to dealers during the month.</p>\n<p>Xpeng Chairman<b>Brian Gu</b>said last month the company aims to sell half of its electric vehicles outside of China.</p>\n<p>The maker of electric sedans and SUVs already sells electric vehicles in Norway and plans to ramp up investments overseas next year, including in Sweden, Denmark and the Netherlands.</p>\n<p>The Shanghai-based Nio has similar plans and said last week it plans to foray into Germany, the Netherlands, Sweden and Denmark in 2022 and aims to have a presence in 25 countries by 2025.</p>\n<p>Ark Invest first bought shares in Xpeng on Dec. 3 and has since piled up shares in the electric vehicle company’s stock on six days, all via the <b>Ark</b> <b>Autonomous Technology & Robotics ETF</b>(BATS:ARKQ).</p>\n<p>ARKQ held 637,042 shares — worth $27.88 million in Xpeng, prior to Thursday’s trade.</p>\n<p>Besides Xpeng, the Elon Musk-led Tesla is the only all-electric vehicle maker in which Ark Invest has bought large amounts. The firm counts Tesla as its largest holding and owns shares worth billions in the company via its exchange-traded funds.</p>\n<p>The investment firm has been booking profit in Tesla since early September when shares of the company began an upward march.</p>\n<p>Ark also sold 2,273 shares — estimated to be worth $6.68 million — in <b>Alphabet Inc Class C</b>(NASDAQ:GOOG). The stock closed 1.89% higher at $2,938.9 a share on Wednesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title> Cathie Wood Loads Up Another $800K In This Chinese Tesla Rival Ahead Of Its Overseas Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n Cathie Wood Loads Up Another $800K In This Chinese Tesla Rival Ahead Of Its Overseas Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-23 19:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Cathie Wood</b>’s <b>Ark Investment Management</b> on Friday loaded up another 18,000 shares — worth about $823,320 — in the U.S. listed Chinese electric vehicle maker <b>Xpeng Inc</b>(NYSE:XPEV).</p>\n<p>Xpeng’s stock closed 4.5% higher at $44.47 a share on Wednesday. The stock is up about 3.7% fp or the year.</p>\n<p>The Guangzhou, China-based company bolted ahead of local rivals Nio and <b>Li Auto Inc</b>(NASDAQ:LI) last month with deliveries.</p>\n<p>Each of the three players delivered more than 10,000 electric vehicles — with Xpeng leading the pack at 15,613 units, Li Auto grabbing the second spot at 13,485 units and Nio dispatching 10,878 units to dealers during the month.</p>\n<p>Xpeng Chairman<b>Brian Gu</b>said last month the company aims to sell half of its electric vehicles outside of China.</p>\n<p>The maker of electric sedans and SUVs already sells electric vehicles in Norway and plans to ramp up investments overseas next year, including in Sweden, Denmark and the Netherlands.</p>\n<p>The Shanghai-based Nio has similar plans and said last week it plans to foray into Germany, the Netherlands, Sweden and Denmark in 2022 and aims to have a presence in 25 countries by 2025.</p>\n<p>Ark Invest first bought shares in Xpeng on Dec. 3 and has since piled up shares in the electric vehicle company’s stock on six days, all via the <b>Ark</b> <b>Autonomous Technology & Robotics ETF</b>(BATS:ARKQ).</p>\n<p>ARKQ held 637,042 shares — worth $27.88 million in Xpeng, prior to Thursday’s trade.</p>\n<p>Besides Xpeng, the Elon Musk-led Tesla is the only all-electric vehicle maker in which Ark Invest has bought large amounts. The firm counts Tesla as its largest holding and owns shares worth billions in the company via its exchange-traded funds.</p>\n<p>The investment firm has been booking profit in Tesla since early September when shares of the company began an upward march.</p>\n<p>Ark also sold 2,273 shares — estimated to be worth $6.68 million — in <b>Alphabet Inc Class C</b>(NASDAQ:GOOG). The stock closed 1.89% higher at $2,938.9 a share on Wednesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","09868":"小鹏汽车-W"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187215359","content_text":"Cathie Wood’s Ark Investment Management on Friday loaded up another 18,000 shares — worth about $823,320 — in the U.S. listed Chinese electric vehicle maker Xpeng Inc(NYSE:XPEV).\nXpeng’s stock closed 4.5% higher at $44.47 a share on Wednesday. The stock is up about 3.7% fp or the year.\nThe Guangzhou, China-based company bolted ahead of local rivals Nio and Li Auto Inc(NASDAQ:LI) last month with deliveries.\nEach of the three players delivered more than 10,000 electric vehicles — with Xpeng leading the pack at 15,613 units, Li Auto grabbing the second spot at 13,485 units and Nio dispatching 10,878 units to dealers during the month.\nXpeng ChairmanBrian Gusaid last month the company aims to sell half of its electric vehicles outside of China.\nThe maker of electric sedans and SUVs already sells electric vehicles in Norway and plans to ramp up investments overseas next year, including in Sweden, Denmark and the Netherlands.\nThe Shanghai-based Nio has similar plans and said last week it plans to foray into Germany, the Netherlands, Sweden and Denmark in 2022 and aims to have a presence in 25 countries by 2025.\nArk Invest first bought shares in Xpeng on Dec. 3 and has since piled up shares in the electric vehicle company’s stock on six days, all via the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ).\nARKQ held 637,042 shares — worth $27.88 million in Xpeng, prior to Thursday’s trade.\nBesides Xpeng, the Elon Musk-led Tesla is the only all-electric vehicle maker in which Ark Invest has bought large amounts. The firm counts Tesla as its largest holding and owns shares worth billions in the company via its exchange-traded funds.\nThe investment firm has been booking profit in Tesla since early September when shares of the company began an upward march.\nArk also sold 2,273 shares — estimated to be worth $6.68 million — in Alphabet Inc Class C(NASDAQ:GOOG). The stock closed 1.89% higher at $2,938.9 a share on Wednesday.","news_type":1,"symbols_score_info":{"09868":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":1547,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691987547,"gmtCreate":1640126459593,"gmtModify":1640126459833,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691987547","repostId":"1154778445","repostType":4,"repost":{"id":"1154778445","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640099685,"share":"https://ttm.financial/m/news/1154778445?lang=&edition=full","pubTime":"2021-12-21 23:14","market":"us","language":"en","title":"Travel and leisure stocks gained in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1154778445","media":"Tiger Newspress","summary":"Travel and leisure stocks gained in early trading. UAl, AAL, DAL and LUV shares were up between 4% a","content":"<p>Travel and leisure stocks gained in early trading. UAl, AAL, DAL and LUV shares were up between 4% and 7%.</p>\n<p>CCL, RCL and NCLH shares rose between 5% and 8%.<img src=\"https://static.tigerbbs.com/99687d6e84a5baa64ead27263c83b24f\" tg-width=\"977\" tg-height=\"429\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/73210a8a9af665735a288bce4bf3b1cd\" tg-width=\"998\" tg-height=\"340\" referrerpolicy=\"no-referrer\">The Omicron coronavirus variant is rapidly spreading across the U.S. just as the holiday season’s busiest travel period gets under way.</p>\n<p>However, there appear to be no signs yet of the new variant significantly affecting air travel in the U.S. in the run up to Christmas.</p>\n<p>More than two million people passed through airport security checkpoints on Monday for the fifth consecutive day, according to Transportation Security Administration data. The numbers have been tracking at between 81% and 85% of traveler throughput against the same days in 2019, although the peak holiday travel days are ahead.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travel and leisure stocks gained in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravel and leisure stocks gained in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-21 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Travel and leisure stocks gained in early trading. UAl, AAL, DAL and LUV shares were up between 4% and 7%.</p>\n<p>CCL, RCL and NCLH shares rose between 5% and 8%.<img src=\"https://static.tigerbbs.com/99687d6e84a5baa64ead27263c83b24f\" tg-width=\"977\" tg-height=\"429\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/73210a8a9af665735a288bce4bf3b1cd\" tg-width=\"998\" tg-height=\"340\" referrerpolicy=\"no-referrer\">The Omicron coronavirus variant is rapidly spreading across the U.S. just as the holiday season’s busiest travel period gets under way.</p>\n<p>However, there appear to be no signs yet of the new variant significantly affecting air travel in the U.S. in the run up to Christmas.</p>\n<p>More than two million people passed through airport security checkpoints on Monday for the fifth consecutive day, according to Transportation Security Administration data. The numbers have been tracking at between 81% and 85% of traveler throughput against the same days in 2019, although the peak holiday travel days are ahead.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UAL":"联合大陆航空","CCL":"嘉年华邮轮","LUV":"西南航空","NCLH":"挪威邮轮","RCL":"皇家加勒比邮轮","AAL":"美国航空","DAL":"达美航空"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154778445","content_text":"Travel and leisure stocks gained in early trading. UAl, AAL, DAL and LUV shares were up between 4% and 7%.\nCCL, RCL and NCLH shares rose between 5% and 8%.The Omicron coronavirus variant is rapidly spreading across the U.S. just as the holiday season’s busiest travel period gets under way.\nHowever, there appear to be no signs yet of the new variant significantly affecting air travel in the U.S. in the run up to Christmas.\nMore than two million people passed through airport security checkpoints on Monday for the fifth consecutive day, according to Transportation Security Administration data. The numbers have been tracking at between 81% and 85% of traveler throughput against the same days in 2019, although the peak holiday travel days are ahead.","news_type":1,"symbols_score_info":{"AAL":0.9,"CCL":0.9,"DAL":0.9,"LUV":0.9,"NCLH":0.9,"RCL":0.9,"UAL":0.9}},"isVote":1,"tweetType":1,"viewCount":1476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693418755,"gmtCreate":1640060390314,"gmtModify":1640060955734,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/693418755","repostId":"2192358181","repostType":4,"repost":{"id":"2192358181","kind":"highlight","pubTimestamp":1640055937,"share":"https://ttm.financial/m/news/2192358181?lang=&edition=full","pubTime":"2021-12-21 11:05","market":"us","language":"en","title":"3 Growth Stocks That Could Skyrocket 50% or More in 2022, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2192358181","media":"Motley Fool","summary":"There are good reasons for Wall Street analysts to be bullish about these stocks.","content":"<p>Want to have a really happy new year? Invest now in stocks that are likely to really take off in 2022. Granted, that's easier said than done. There's no way to know for sure which stocks will perform well in the future.</p>\n<p>However, you can get some ideas from the analysts getting paid big bucks to research companies from top to bottom. Here are three growth stocks that will skyrocket 50% or more in 2022, according to Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F657145%2F2022-businessman-with-charts.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"423\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Sea Limited</h2>\n<p>The consensus 12-month price target for <b>Sea Limited</b> (NYSE:SE) reflects an upside potential of 89%. Sea wasn't too far away from achieving that target in October. However, the stock has plunged more than 40% from its high -- in part due to the company badly missing Q3 earnings expectations but mainly because of the overall sell-off of growth stocks.</p>\n<p>Sea's past success has been primarily driven by its <i>Free Fire</i> mobile game. Although <i>Free Fire</i> was launched four years ago, it's still the highest-grossing mobile game in India, Latin America,and Southeast Asia, according to App Annie. It has also been the highest-grossing mobile battle royale game in the U.S. for three consecutive quarters. Sea expects even more growth as it rolls out new features.</p>\n<p>But don't think of Sea Limited as just a video game stock. The company's Shopee e-commerce platform dominates in the Southeast Asia and Taiwan markets. It's also made significant headway in Latin America.</p>\n<p>Sea also has SeaMoney. It's a top digital payments and financial services provider in Southeast Asia. In the third quarter of 2021, SeaMoney's total payment volume more than doubled year over year.</p>\n<p>Gaming, e-commerce, and digital payments are all strong growth markets. There aren't many companies that have the potential to win in all three, but Sea Limited could.</p>\n<h2>2. Teladoc Health</h2>\n<p><b>Teladoc Health</b>'s (NYSE:TDOC) shares are down more than 50% year to date. But Wall Street thinks this virtual care leader could rebound in a major way in 2022. The consensus price target for Teladoc reflects an upside potential of nearly 66%.</p>\n<p>Why has Teladoc fallen so much? One main factor is that some investors thought that the end of COVID-19 lockdowns would lead to slowing growth. While Teladoc did experience some slowing, its business continues to perform very well.</p>\n<p>The company's near-term prospects look quite good. Teladoc's contract with HCSC, the fifth-biggest health insurer in the U.S., goes into effect in January 2022. Primary360, Teladoc's virtual primary care service, also continues to gain momentum.</p>\n<p>Teladoc's long-term prospects should be even better. We're still only in the early innings of the adoption of virtual care. Sure, there are other companies competing against Teladoc. However, the company has a wider moat than you might think as the largest player in the industry.</p>\n<h2>3. <a href=\"https://laohu8.com/S/PYPL\">PayPal</a></h2>\n<p><b>PayPal Holdings</b> (NASDAQ:PYPL) has fallen more in recent months than it has since the fintech stock first traded publicly as a stand-alone entity in 2015. Analysts think this decline will be only temporary, though. The consensus price target for PayPal is 50% higher than its current share price.</p>\n<p>Wall Street's optimism could be well-founded. PayPal ranks as the most accepted digital wallet in the world. More than 75% of the top 1,500 biggest merchants allow customers to pay with PayPal. As e-commerce grows, so will PayPal.</p>\n<p>New features should enable PayPal to gain even more momentum. The app's cryptocurrency wallet has been a big hit. PayPal plans to launch high-yield savings to the app in early 2022.</p>\n<p>PayPal's Venmo mobile payment app should also enjoy a significant boost next year. <b>Amazon.com</b> will allow customers to make purchases with their Venmo accounts beginning in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks That Could Skyrocket 50% or More in 2022, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks That Could Skyrocket 50% or More in 2022, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 11:05 GMT+8 <a href=https://www.fool.com/investing/2021/12/20/growth-stocks-skyrocket-2022-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Want to have a really happy new year? Invest now in stocks that are likely to really take off in 2022. Granted, that's easier said than done. There's no way to know for sure which stocks will perform ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/20/growth-stocks-skyrocket-2022-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4566":"资本集团","TDOC":"Teladoc Health Inc.","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","PYPL":"PayPal","BK4106":"数据处理与外包服务","BK4524":"宅经济概念","BK4535":"淡马锡持仓","BK4504":"桥水持仓","BK4167":"医疗保健技术","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4554":"元宇宙及AR概念","BK4085":"互动家庭娱乐","SE":"Sea Ltd","BK4548":"巴美列捷福持仓","BK4503":"景林资产持仓","BK4527":"明星科技股"},"source_url":"https://www.fool.com/investing/2021/12/20/growth-stocks-skyrocket-2022-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192358181","content_text":"Want to have a really happy new year? Invest now in stocks that are likely to really take off in 2022. Granted, that's easier said than done. There's no way to know for sure which stocks will perform well in the future.\nHowever, you can get some ideas from the analysts getting paid big bucks to research companies from top to bottom. Here are three growth stocks that will skyrocket 50% or more in 2022, according to Wall Street.\nImage source: Getty Images.\n1. Sea Limited\nThe consensus 12-month price target for Sea Limited (NYSE:SE) reflects an upside potential of 89%. Sea wasn't too far away from achieving that target in October. However, the stock has plunged more than 40% from its high -- in part due to the company badly missing Q3 earnings expectations but mainly because of the overall sell-off of growth stocks.\nSea's past success has been primarily driven by its Free Fire mobile game. Although Free Fire was launched four years ago, it's still the highest-grossing mobile game in India, Latin America,and Southeast Asia, according to App Annie. It has also been the highest-grossing mobile battle royale game in the U.S. for three consecutive quarters. Sea expects even more growth as it rolls out new features.\nBut don't think of Sea Limited as just a video game stock. The company's Shopee e-commerce platform dominates in the Southeast Asia and Taiwan markets. It's also made significant headway in Latin America.\nSea also has SeaMoney. It's a top digital payments and financial services provider in Southeast Asia. In the third quarter of 2021, SeaMoney's total payment volume more than doubled year over year.\nGaming, e-commerce, and digital payments are all strong growth markets. There aren't many companies that have the potential to win in all three, but Sea Limited could.\n2. Teladoc Health\nTeladoc Health's (NYSE:TDOC) shares are down more than 50% year to date. But Wall Street thinks this virtual care leader could rebound in a major way in 2022. The consensus price target for Teladoc reflects an upside potential of nearly 66%.\nWhy has Teladoc fallen so much? One main factor is that some investors thought that the end of COVID-19 lockdowns would lead to slowing growth. While Teladoc did experience some slowing, its business continues to perform very well.\nThe company's near-term prospects look quite good. Teladoc's contract with HCSC, the fifth-biggest health insurer in the U.S., goes into effect in January 2022. Primary360, Teladoc's virtual primary care service, also continues to gain momentum.\nTeladoc's long-term prospects should be even better. We're still only in the early innings of the adoption of virtual care. Sure, there are other companies competing against Teladoc. However, the company has a wider moat than you might think as the largest player in the industry.\n3. PayPal\nPayPal Holdings (NASDAQ:PYPL) has fallen more in recent months than it has since the fintech stock first traded publicly as a stand-alone entity in 2015. Analysts think this decline will be only temporary, though. The consensus price target for PayPal is 50% higher than its current share price.\nWall Street's optimism could be well-founded. PayPal ranks as the most accepted digital wallet in the world. More than 75% of the top 1,500 biggest merchants allow customers to pay with PayPal. As e-commerce grows, so will PayPal.\nNew features should enable PayPal to gain even more momentum. The app's cryptocurrency wallet has been a big hit. PayPal plans to launch high-yield savings to the app in early 2022.\nPayPal's Venmo mobile payment app should also enjoy a significant boost next year. Amazon.com will allow customers to make purchases with their Venmo accounts beginning in 2022.","news_type":1,"symbols_score_info":{"PYPL":0.9,"SE":0.9,"TDOC":0.9}},"isVote":1,"tweetType":1,"viewCount":2552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693868032,"gmtCreate":1640002506400,"gmtModify":1640002506584,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Sell?","listText":"Sell?","text":"Sell?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693868032","repostId":"1177944784","repostType":4,"repost":{"id":"1177944784","kind":"news","pubTimestamp":1639999788,"share":"https://ttm.financial/m/news/1177944784?lang=&edition=full","pubTime":"2021-12-20 19:29","market":"us","language":"en","title":"Omicron Fears Ignite Market Selloff Just as Traders Clear Books","url":"https://stock-news.laohu8.com/highlight/detail?id=1177944784","media":"Bloomberg","summary":"(Bloomberg) -- Just as investors were wrapping up this year’s trading, the threat of new lockdowns s","content":"<p>(Bloomberg) -- Just as investors were wrapping up this year’s trading, the threat of new lockdowns sent shock waves through markets across the world.</p>\n<p>Sentiment in stocks and bonds remained on the back foot, though U.S. stock index futures and 10-year Treasury yields pared declines after Moderna Inc. said a third dose of its Covid-19 vaccine increased antibody levels against the omicron variant.</p>\n<p>Lockdown risks are rising, with the U.K. Health Secretary Sajid Javid refusing to rule out stronger measures before Christmas and the Netherlands said Saturday it’s going to a full lockdown until at least Jan. 14. Senator Joe Manchin’s rejection of the U.S. spending package at the heart of President Joe Biden’s economic agenda also weighed on sentiment.</p>\n<p>“The market is lowering its expectations for growth due to omicron and lower liquidity as the year is ending is potentially amplifying the moves, so we have to be a bit careful of reading too much into the weakness,” said Peter Garnry, head of equity strategy at Saxo Bank.</p>\n<p><b>Volatility Jumps</b></p>\n<p>Volatility surged, with the Euro Stoxx 50 Volatility VSTOXX Index and the VIX Index both jumping to the highest in two weeks.</p>\n<p>S&P 500 e-mini futures fell 1.2% as of 6:01 a.m. in New York, after earlier sliding as much as 1.8%. The Stoxx Europe 600 Index trimmed earlier declines to 1.5%.</p>\n<p>“I remain constructive for 2022, given a health situation that seems under control, with admittedly high transmissibility but mild symptoms; an environment of interest rates increasing but nonetheless contained, as well as an inflation that seems under control,” said Michel Keusch, a portfolio manager at Bellevue Asset Management. “I would not sell in this environment.”</p>\n<p>Yields on 10-year Treasuries traded at 1.39%, paring declines to two basis points. Those on benchmark gilts fell the same amount to 0.74%. Risk-sensitive currencies underperformed, with the New Zealand dollar and pound leading losses in the Group of 10.</p>\n<p>“The selloff is influenced by year-end volatility and new fears on growth due to the omicron variant,” said Antonio Amendola, a portfolio manager at AcomeA Sgr. “That said, we need to remain selective on stories with greater solidity and ability to preserve margins in inflationary contexts. At the relative level, small and mid caps are better than large caps.”</p>\n<p><b>‘Very Jittery’</b></p>\n<p>Morgan Stanley strategists led by Michael Wilson recommended that U.S. stock investors stay defensive, and while omicron adds to economic concerns, they’re more focused on risks of supply picking up while consumption fades.</p>\n<p>“The market is very jittery and obviously the news flow on omicron is not good,” said Charles Diebel, a money manager at Mediolanum. “But I’m not sure the impact will last too long. I think the combination of infections and boosters means this abates relatively quickly, i.e. by February, so I wouldn’t be buying bonds on the back of it.”</p>\n<p>Goldman Sachs Group Inc. cut its forecast for U.S. economic growth in the wake of Manchin’s move against the Biden administration’s roughly $2 trillion tax-and-spend program. Goldman slashed its real gross domestic product projection for the first quarter to 2% from 3% previously.</p>\n<p>The backdrop of monetary-stimulus tapering in major economies is also adding to trouble for developing-nation assets.</p>\n<p>The removal of accommodative monetary policy by many major central banks “will hit emerging markets hard”, along with other risk assets that are dependent on plentiful liquidity, according to Win Thin, global head of currency strategy at Brown Brothers Harriman & Co. “EM is likely to remain under pressure as we move into 2022.”</p>\n<p><b>Emerging Markets</b></p>\n<p>Every developing-market currency except the yuan has weakened against the greenback over the past six months. The Turkish lira, which has been under pressure after President Recep Erdogan flagged an economic model that relies on lower borrowing costs, slid to an all-time low on Monday.</p>\n<p>In stocks, the MSCI Emerging Markets Index has slid more than 7% this year and was down 1.9% today.</p>\n<p>On Friday, the S&P 500 gauge extended its weekly slide in a session of heavy trading volume. With the holidays fast approaching, it could have been the last day of 2021 with enough liquidity for investors to trade in and out of large positions.</p>\n<p>“Unless we see this flow turn around then it feels like we could be at the mercy of position squaring, rather than chasing, and longs taking some off the table ahead of the calendar year-end,” Chris Weston, head of research with Pepperstone Financial Pty Ltd., wrote in a note to clients.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omicron Fears Ignite Market Selloff Just as Traders Clear Books</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmicron Fears Ignite Market Selloff Just as Traders Clear Books\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-20 19:29 GMT+8 <a href=https://finance.yahoo.com/news/u-stock-index-futures-fall-030733739.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Just as investors were wrapping up this year’s trading, the threat of new lockdowns sent shock waves through markets across the world.\nSentiment in stocks and bonds remained on the back...</p>\n\n<a href=\"https://finance.yahoo.com/news/u-stock-index-futures-fall-030733739.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/u-stock-index-futures-fall-030733739.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177944784","content_text":"(Bloomberg) -- Just as investors were wrapping up this year’s trading, the threat of new lockdowns sent shock waves through markets across the world.\nSentiment in stocks and bonds remained on the back foot, though U.S. stock index futures and 10-year Treasury yields pared declines after Moderna Inc. said a third dose of its Covid-19 vaccine increased antibody levels against the omicron variant.\nLockdown risks are rising, with the U.K. Health Secretary Sajid Javid refusing to rule out stronger measures before Christmas and the Netherlands said Saturday it’s going to a full lockdown until at least Jan. 14. Senator Joe Manchin’s rejection of the U.S. spending package at the heart of President Joe Biden’s economic agenda also weighed on sentiment.\n“The market is lowering its expectations for growth due to omicron and lower liquidity as the year is ending is potentially amplifying the moves, so we have to be a bit careful of reading too much into the weakness,” said Peter Garnry, head of equity strategy at Saxo Bank.\nVolatility Jumps\nVolatility surged, with the Euro Stoxx 50 Volatility VSTOXX Index and the VIX Index both jumping to the highest in two weeks.\nS&P 500 e-mini futures fell 1.2% as of 6:01 a.m. in New York, after earlier sliding as much as 1.8%. The Stoxx Europe 600 Index trimmed earlier declines to 1.5%.\n“I remain constructive for 2022, given a health situation that seems under control, with admittedly high transmissibility but mild symptoms; an environment of interest rates increasing but nonetheless contained, as well as an inflation that seems under control,” said Michel Keusch, a portfolio manager at Bellevue Asset Management. “I would not sell in this environment.”\nYields on 10-year Treasuries traded at 1.39%, paring declines to two basis points. Those on benchmark gilts fell the same amount to 0.74%. Risk-sensitive currencies underperformed, with the New Zealand dollar and pound leading losses in the Group of 10.\n“The selloff is influenced by year-end volatility and new fears on growth due to the omicron variant,” said Antonio Amendola, a portfolio manager at AcomeA Sgr. “That said, we need to remain selective on stories with greater solidity and ability to preserve margins in inflationary contexts. At the relative level, small and mid caps are better than large caps.”\n‘Very Jittery’\nMorgan Stanley strategists led by Michael Wilson recommended that U.S. stock investors stay defensive, and while omicron adds to economic concerns, they’re more focused on risks of supply picking up while consumption fades.\n“The market is very jittery and obviously the news flow on omicron is not good,” said Charles Diebel, a money manager at Mediolanum. “But I’m not sure the impact will last too long. I think the combination of infections and boosters means this abates relatively quickly, i.e. by February, so I wouldn’t be buying bonds on the back of it.”\nGoldman Sachs Group Inc. cut its forecast for U.S. economic growth in the wake of Manchin’s move against the Biden administration’s roughly $2 trillion tax-and-spend program. Goldman slashed its real gross domestic product projection for the first quarter to 2% from 3% previously.\nThe backdrop of monetary-stimulus tapering in major economies is also adding to trouble for developing-nation assets.\nThe removal of accommodative monetary policy by many major central banks “will hit emerging markets hard”, along with other risk assets that are dependent on plentiful liquidity, according to Win Thin, global head of currency strategy at Brown Brothers Harriman & Co. “EM is likely to remain under pressure as we move into 2022.”\nEmerging Markets\nEvery developing-market currency except the yuan has weakened against the greenback over the past six months. The Turkish lira, which has been under pressure after President Recep Erdogan flagged an economic model that relies on lower borrowing costs, slid to an all-time low on Monday.\nIn stocks, the MSCI Emerging Markets Index has slid more than 7% this year and was down 1.9% today.\nOn Friday, the S&P 500 gauge extended its weekly slide in a session of heavy trading volume. With the holidays fast approaching, it could have been the last day of 2021 with enough liquidity for investors to trade in and out of large positions.\n“Unless we see this flow turn around then it feels like we could be at the mercy of position squaring, rather than chasing, and longs taking some off the table ahead of the calendar year-end,” Chris Weston, head of research with Pepperstone Financial Pty Ltd., wrote in a note to clients.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699714335,"gmtCreate":1639894654830,"gmtModify":1639894655036,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"themes":[],"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699714335","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://ttm.financial/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8 <a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓","CERN":"美国塞纳","ORCL":"甲骨文","ARNA":"阿里那","PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals dominated with a ~83.8% rise after Pfizer agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle for the electronic-medical-records company.\nVaccine developer, Novavax jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1,"symbols_score_info":{"ARNA":0.9,"CERN":0.9,"ORCL":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}